The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Complexities of TGF-β Targeted Cancer Therapy
Open accessAbstract
Many advanced tumors produce excessive amounts of Transforming Growth Factor-β (TGF-β) which, in normal epithelial cells, is a potent growth inhibitor. However, in oncogenically activated cells, the homeostatic action of TGF-β is often diverted along alternative pathways. Hence, TGF-β signaling elicits protective or tumor suppressive effects during the early growth-sensitive stages of tumorigenesis. However, later in tumor development when carcinoma cells become refractory to TGF-β-mediated growth inhibition, the tumor cell responds by stimulating pathways with tumor progressing effects. At late stages of malignancy, tumor progression is driven by TGF-β overload. The tumor microenvironment is a target of TGF-β action that stimulates tumor progression via pro-tumorigenic effects on vascular, immune, and fibroblastic cells. Bone is one of the richest sources of TGF-β in the body and a common site for dissemination of breast cancer metastases. Osteoclastic degradation of bone matrix, which accompanies establishment and growth of metastases, triggers further release of bone-derived TGF-β. This leads to a vicious positive feedback of tumor progression, driven by ever increasing levels of TGF-β released from both the tumor and bone matrix. It is for this reason, that pharmaceutical companies have developed therapeutic agents that block TGF-β signaling. Nonetheless, the choice of drug design and dosing strategy can affect the efficacy of TGF-β therapeutics. This review will describe pre-clinical and clinical data of four major classes of TGF-β inhibitor, namely i) ligand traps, ii) antisense oligonucleotides, iii) receptor kinase inhibitors and iv) peptide aptamers. Long term dosing strategies with TGF-β inhibitors may be ill-advised, since this class of drug has potentially highly pleiotropic activity, and development of drug resistance might potentiate tumor progression. Current paradigms for the use of TGF-β inhibitors in oncology have therefore moved towards the use of combinatorial therapies and short term dosing, with considerable promise for the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus
Shi, Y., & Massagué, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00432-x · Cited by 5,857
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,088
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
Self-citationMunger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Kingsley, D. M. (1994) · Genes & Development · doi:10.1101/gad.8.2.133 · Cited by 1,933
Massagué, J. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35043051 · Cited by 1,899
EMT, the cytoskeleton, and cancer cell invasion
Yilmaz, M., & Christofori, G. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9169-0 · Cited by 1,788
Inman, G. J., Nicolás, F. J., Callahan, J. F., Harling, J. D., Gaster, L. M., Reith, A. D., Laping, N. J., & Hill, C. S. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.1.65 · Cited by 1,634
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1208 · Cited by 1,604
Macrophages, innate immunity and cancer: balance, tolerance, and diversity
Mantovani, A., & Sica, A. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.009 · Cited by 1,484
Growth factors from murine sarcoma virus-transformed cells.
de Larco, J. E., & Todaro, G. J. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.8.4001 · Cited by 1,461
TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia
Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., Washington, M. K., Neilson, E. G., & Moses, H. L. (2004) · Science · doi:10.1126/science.1090922 · Cited by 1,401
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
TGFβ signalling: a complex web in cancer progression
Ikushima, H., & Miyazono, K. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2853 · Cited by 1,173
The polarization of immune cells in the tumour environment by TGFβ
Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limón, P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2808 · Cited by 940
Miettinen, P. J., Ebner, R., Lopez, A. R., & Derynck, R. (1994) · The Journal of cell biology · doi:10.1083/jcb.127.6.2021 · Cited by 937
Roberts, A. B., Anzano, M. A., Lamb, L. C., Smith, J. M., & Sporn, M. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5339 · Cited by 919
Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., Carbone, D. P., Matrisian, L. M., Richmond, A., Lin, P. C., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.004 · Cited by 918
Derynck, R., Goeddel, D. V., Ullrich, A., Gutterman, J. U., Williams, R. D., Bringman, T. S., & Berger, W. H. (1987) · PubMed · Cited by 898
TGF-β signaling: positive and negative effects on tumorigenesis
Wakefield, L. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00259-3 · Cited by 827
Padua, D., & Massagué, J. (2009) · Cell Research · doi:10.1038/cr.2008.316 · Cited by 809
Gorelik, L., & Flavell, R. A. (2001) · Nature Medicine · doi:10.1038/nm1001-1118 · Cited by 770
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Bardelli, A., & Siena, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6116 · Cited by 746
TGF-β Superfamily Signaling in Embryonic Development and Homeostasis
Wu, M. Y., & Hill, C. S. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.02.012 · Cited by 746
Integration of TGF‐β/Smad and Jagged1/Notch signalling in epithelial‐to‐mesenchymal transition
Zavadil, J., Cermak, L., Soto‐Nieves, N., & Böttinger, E. P. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600069 · Cited by 746
Parsons, R. E., Myeroff, L. L., Liu, B., Willson, J. K. V., Markowitz, S. D., Kinzler, K. W., & Vogelstein, B. (1995) · PubMed · Cited by 738
Oft, M., Peli, J., Rudaz, C., Schwarz, H., Beug, H., & Reichmann, E. (1996) · Genes & Development · doi:10.1101/gad.10.19.2462 · Cited by 681
Laping, N. J., Grygielko, E., Mathur, A., Butter, S., Bomberger, J., Tweed, C., Martin, W., Fornwald, J., Lehr, R., Harling, J., et al. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.1.58 · Cited by 635
Cui, W., Fowlis, D. J., Bryson, S., Duffie, E., Ireland, H., Balmain, A., & Akhurst, R. J. (1996) · Cell · doi:10.1016/s0092-8674(00)80127-0 · Cited by 628
Self-citationTRAF6 Mediates Smad-Independent Activation of JNK and p38 by TGF-β
Yamashita, M., Fatyol, K., Jin, C., Wang, X., Liu, Z., & Zhang, Y. E. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.09.002 · Cited by 559
The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner
Sorrentino, A., Thakur, N., Grimsby, S., Marcusson, A., von Bulow, V., Schuster, N., Zhang, S., Heldin, C.-H., & Landström, M. (2008) · Nature Cell Biology · doi:10.1038/ncb1780 · Cited by 553
Alterations in components of the TGF-β superfamily signaling pathways in human cancer
LEVY, L., & HILL, C. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.009 · Cited by 539
Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer
Pardali, K., & Moustakas, A. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.06.004 · Cited by 526
Cartilage-inducing factor-A. Apparent identity to transforming growth factor-beta.
Seyedin, S. M., Thompson, A. Y., Bentz, H., Rosen, D. M., McPherson, J. M., Conti, A., Siegel, N. R., Galluppi, G. R., & Piez, K. A. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38436-3 · Cited by 521
Transforming growth factor production by chemically transformed cells.
Moses, H. L., Branum, E. L., Proper, J. A., & Robinson, R. A. (1981) · PubMed · Cited by 497
TGFβ influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b
Seoane, J., Pouponnot, C., Staller, P., Schader, M., Eilers, M., & Massagué, J. (2001) · Nature Cell Biology · doi:10.1038/35070086 · Cited by 489
Morris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090353 · Cited by 487
E2F4/5 and p107 as Smad Cofactors Linking the TGFβ Receptor to c-myc Repression
Chen, C.-R., Kang, Y., Siegel, P. M., & Massagué, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00801-2 · Cited by 487
Roberts, A. B., Lamb, L. C., Newton, D. L., Sporn, M. B., De Larco, J. E., & Todaro, G. J. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.6.3494 · Cited by 448
Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq142 · Cited by 433
Piek, E., Moustakas, A., Kurisaki, A., Heldin, C.-H., & Dijke, P. T. (1999) · Journal of Cell Science · doi:10.1242/jcs.112.24.4557 · Cited by 426
Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases
Muraoka, R. S., Dumont, N., Ritter, C. A., Dugger, T. C., Brantley, D. M., Chen, J., Easterly, E., Roebuck, L. R., Ryan, S., Gotwals, P. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215234 · Cited by 415
Yang, Y.-A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215333 · Cited by 404
Yang, Y.-A., Dukhanina, O. I., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J. D., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15333 · Cited by 404
Differentiation plasticity regulated by TGF-β family proteins in development and disease
Derynck, R., & Akhurst, R. J. (2007) · Nature Cell Biology · doi:10.1038/ncb434 · Cited by 382
Self-citationMetastasis is driven by sequential elevation of H-ras and Smad2 levels
Oft, M., Akhurst, R. J., & Balmain, A. (2002) · Nature Cell Biology · doi:10.1038/ncb807 · Cited by 373
Self-citationFoxp3 Expression in Pancreatic Carcinoma Cells as a Novel Mechanism of Immune Evasion in Cancer
Hinz, S., Pagerols-Raluy, L., Oberg, H.-H., Ammerpohl, O., Grüssel, S., Sipos, B., Grützmann, R., Pilarsky, C., Ungefroren, H., Saeger, H.-D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3304 · Cited by 352
Corcoran, R. B., Dias-Santagata, D., Bergethon, K., Iafrate, A. J., Settleman, J., & Engelman, J. A. (2010) · Science Signaling · doi:10.1126/scisignal.2001148 · Cited by 350
Tojo, M., Hamashima, Y., Hanyu, A., Kajimoto, T., Saitoh, M., Miyazono, K., Node, M., & Imamura, T. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00103.x · Cited by 339
Tumor microenvironments direct the recruitment and expansion of human Th17 cells
Su, X., Ye, J., Hsueh, E. C., Zhang, Y., Hoft, D. F., & Peng, G. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902813 · Cited by 324
Melisi, D., Ishiyama, S., Sclabas, G. M., Fleming, J. B., Xia, Q., Tortora, G., Abbruzzese, J. L., & Chiao, P. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0337 · Cited by 323
Mammary tumor suppression by transforming growth factor beta 1 transgene expression.
Pierce, D. F., Gorska, A. E., Chytil, A., Meise, K. S., Page, D. L., Coffey, R. J., & Moses, H. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4254 · Cited by 291
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Engelman, J. A., & Settleman, J. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.004 · Cited by 284
Wagner, K.-U., Boulanger, C. A., Henry, M. D., Sgagias, M., Hennighausen, L., & Smith, G. H. (2002) · Development · doi:10.1242/dev.129.6.1377 · Cited by 274
C/EBPβ at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells
Gomis, R. R., Alarcón, C., Nadal, C., Van Poznak, C., & Massagué, J. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.019 · Cited by 273
Battula, V. L., Evans, K. W., Hollier, B. G., Shi, Y., Marini, F. C., Ayyanan, A., Wang, R.-Y., Brisken, C., Guerra, R., Andreeff, M., et al. (2010) · Stem Cells · doi:10.1002/stem.467 · Cited by 266
Nam, J.-S., Terabe, M., Kang, M.-J., Chae, H., Voong, N., Yang, Y.-A., Laurence, A., Michalowska, A., Mamura, M., Lonning, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0206 · Cited by 251
Zhang, M., Kleber, S., Röhrich, M., Timke, C., Han, N., Tuettenberg, J., Martin-Villalba, A., Debus, J., Peschke, P., Wirkner, U., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1212 · Cited by 249
Forrester, E., Chytil, A., Bierie, B., Aakre, M., Gorska, A. E., Sharif-Afshar, A.-R., Muller, W. J., & Moses, H. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3272 · Cited by 249
Senturk, S., Mumcuoglu, M., Gursoy-Yuzugullu, O., Cingoz, B., Akcali, K. C., & Ozturk, M. (2010) · Hepatology · doi:10.1002/hep.23769 · Cited by 238
Nam, J.-S., Terabe, M., Mamura, M., Kang, M.-J., Chae, H., Stuelten, C., Kohn, E., Tang, B., Sabzevari, H., Anver, M. R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0215 · Cited by 233
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
Sierra, J. R., Cepero, V., & Giordano, S. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-75 · Cited by 231
Differentiation plasticity regulated by TGF-|[beta]| family proteins in development and disease
Derynck, R., & Akhurst, R. J. (2007) · Nature · doi:10.1038/ncb0907-1000 · Cited by 227
Self-citationEvaluation of Anti-TGF-β2 Antibody as a New Postoperative Anti-scarring Agent in Glaucoma Surgery
Mead, A. L., Wong, T. T. L., Cordeiro, M. F., Anderson, I. K., & Khaw, P. T. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0978 · Cited by 225
Han, G. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24399 · Cited by 224
TGF-β-RI Kinase Inhibitor SD-208 Reduces the Development and Progression of Melanoma Bone Metastases
Mohammad, K. S., Javelaud, D., Fournier, P. G. J., Niewolna, M., McKenna, C. R., Peng, X. H., Duong, V., Dunn, L. K., Mauviel, A., & Guise, T. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2651 · Cited by 221
Korpal, M., Yan, J., Lu, X., Xu, S., Lerit, D. A., & Kang, Y. (2009) · Nature Medicine · doi:10.1038/nm.1943 · Cited by 217
Hau, P., Jachimczak, P., Schlingensiepen, R., Schulmeyer, F., Jauch, T., Steinbrecher, A., Brawanski, A., Proescholdt, M., Schlaier, J., Buchroithner, J., et al. (2007) · Oligonucleotides · doi:10.1089/oli.2006.0053 · Cited by 215
Hoot, K. E., Lighthall, J., Han, G., Lu, S.-L., Li, A., Ju, W., Kulesz-Martin, M., Bottinger, E., & Wang, X.-J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33713 · Cited by 209
Lu, S.-L., Reh, D., Li, A. G., Woods, J., Corless, C. L., Kulesz-Martin, M., & Wang, X.-J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1032 · Cited by 197
Boulanger, C. A., Wagner, K.-U., & Smith, G. H. (2005) · Oncogene · doi:10.1038/sj.onc.1208185 · Cited by 197
Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent.
Cordeiro, M. F., GAY, J. A., & Khaw, P. T. (1999) · PubMed · Cited by 192
Growth factors produced by sarcoma virus-transformed cells.
Todaro, G. J., & Larco, J. E. D. (1978) · PubMed · Cited by 191
Muraoka, R. S., Koh, Y., Roebuck, L. R., Sanders, M. E., Brantley-Sieders, D., Gorska, A. E., Moses, H. L., & Arteaga, C. L. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.23.8691-8703.2003 · Cited by 191
Bandyopadhyay, A., Agyin, J. K., Wang, L., Tang, Y., Lei, X., Story, B. M., Cornell, J. E., Pollock, B. H., Mundy, G. R., & Sun, L.-Z. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3565 · Cited by 185
Portella, G., Cumming, S. A., Liddell, J., Cui, W., Ireland, H., Akhurst, R. J., & Balmain, A. (1998) · PubMed · Cited by 185
Self-citationEhata, S., Hanyu, A., Fujime, M., Katsuno, Y., Fukunaga, E., Goto, K., Ishikawa, Y., Nomura, K., Yokoo, H., Shimizu, T., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2006.00357.x · Cited by 180
Cheng, N., Chytil, A., Shyr, Y., Joly, A., & Moses, H. L. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2203 · Cited by 178
The integrin αVβ6 binds and activates latent TGFβ3
Annes, J. P., Rifkin, D. B., & Munger, J. S. (2002) · FEBS Letters · doi:10.1016/s0014-5793(01)03280-x · Cited by 173
TGF-β Signaling in Breast Cancer Cell Invasion and Bone Metastasis
Drabsch, Y., & ten Dijke, P. (2011) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-011-9217-1 · Cited by 168
Yang, Z., Novak, A. J., Ziesmer, S. C., Witzig, T. E., & Ansell, S. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0266 · Cited by 160
Muraoka-Cook, R. S., Kurokawa, H., Koh, Y., Forbes, J. T., Roebuck, L. R., Barcellos-Hoff, M. H., Moody, S. E., Chodosh, L. A., & Arteaga, C. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2111 · Cited by 159
Kirshner, J., Jobling, M. F., Pajares, M. J., Ravani, S. A., Glick, A. B., Lavin, M. J., Koslov, S., Shiloh, Y., & Barcellos-Hoff, M. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2565 · Cited by 158
Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells
Takahashi, H., Numasaki, M., Lotze, M. T., & Sasaki, H. (2004) · Immunology Letters · doi:10.1016/j.imlet.2004.11.012 · Cited by 153
Transforming growth factor‐beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer
Schlingensiepen, K., Jaschinski, F., Lang, S. A., Moser, C., Geissler, E. K., Schlitt, H. J., Kielmanowicz, M., & Schneider, A. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01917.x · Cited by 143
Transforming growth factor-beta1 mediates cellular response to DNA damage in situ.
Ewan, K., Henshall-Powell, R. L., Ravani, S. A., Pajares, M. J., Arteaga, C. L., Warters, R., Akhurst, R. J., & Barcellos‐Hoff, M. H. (2002) · PubMed · Cited by 142
Self-citationAntitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft.
Bandyopadhyay, A. M., López‐Casillas, F., Malik, S. N., Montiel-Hernández, J. L., Mendoza, V., Yang, J., & Sun, L. (2002) · PubMed · Cited by 140
Ivanović, V., Todorović‐Raković, N., Demajo, M., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00502-6 · Cited by 140
Spees, J. L., Whitney, M. J., Sullivan, D. E., Lasky, J. A., Laboy, M., Ylöstalo, J., & Prockop, D. J. (2007) · The FASEB Journal · doi:10.1096/fj.07-8076com · Cited by 139
TGF-β Inhibition Restores Terminal Osteoblast Differentiation to Suppress Myeloma Growth
Takeuchi, K., Abe, M., Hiasa, M., Oda, A., Amou, H., Kido, S., Harada, T., Tanaka, O., Miki, H., Nakamura, S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009870 · Cited by 138
Bierie, B., Chung, C. H., Parker, J. S., Stover, D. G., Cheng, N., Chytil, A., Aakre, M. E., Shyr, Y., & Moses, H. L. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37480 · Cited by 134
Targeting transforming growth factor-β signaling in liver metastasis of colon cancer
Zhang, B., Halder, S. K., Zhang, S., & Datta, P. K. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.11.035 · Cited by 134
Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis.
Weeks, B. H., He, W., Olson, K. L., & Wang, X. J. (2001) · PubMed · Cited by 120
Glick, A. B., Weinberg, W. C., Wu, I. H., Quan, W., & Yuspa, S. H. (1996) · PubMed · Cited by 117
Smad2 Positively Regulates the Generation of Th17 Cells*
Martínez, G., Zhang, Z., Reynolds, J. M., Tanaka, S., Chung, Y., Liu, T., Robertson, E. J., Lin, X., Feng, X., & Dong, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.c110.155820 · Cited by 109
Mobilization and homing of bone marrow stromal cells in myocardial infarction
Bittira, B. (2003) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/s1010-7940(03)00325-7 · Cited by 109
Horlock, C., Stott, B., Dyson, P. J., Morishita, M., Coombes, R. C., Savage, P. M., & Stebbing, J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604963 · Cited by 107
Defects in TGFβ signaling overcome senescence of mouse keratinocytes expressing v-rasHa
Tremain, R., Marko, M. G., Vijayachandra, K., Ueno, H., Böttinger, E. P., & Glick, A. B. (2000) · Oncogene · doi:10.1038/sj.onc.1203471 · Cited by 107
Smad3 regulates senescence and malignant conversion in a mouse multistage skin carcinogenesis model.
Vijayachandra, K., Lee, J., & Glick, A. B. (2003) · PubMed · Cited by 96
Reducing mammary cancer risk through premature stem cell senescence
Boulanger, C. A., & Smith, G. H. (2001) · Oncogene · doi:10.1038/sj.onc.1204312 · Cited by 93
Biswas, S., Nyman, J. S., Alvarez, J., Chakrabarti, A., Ayres, A., Sterling, J. A. R., Edwards, J., Rana, T., Johnson, R. W., Perrien, D. S., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027090 · Cited by 93
Saito, H., Tsujitani, S., Oka, S., Kondo, A., Ikeguchi, M., Maeta, M., & Kaibara, N. (2000) · PubMed · Cited by 91
Crescenzo, G. D., Hinck, C. S., Shu, Z., Zúñiga, J. E., Yang, J., Tang, Y., Baardsnes, J., Mendoza, V., Sun, L., López‐Casillas, F., et al. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.10.022 · Cited by 90
Fu, K., Corbley, M. J., Sun, L., Friedman, J. E., Shan, F., Papadatos, J. L., Costa, D. E., Lutterodt, F., Sweigard, H., Bowes, S., et al. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.158030 · Cited by 85
Antibody Targeting of TGF-β in Cancer Patients
Lonning, S. M., Mannick, J. B., & McPherson, J. M. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111798808392 · Cited by 84
Connolly, E. C., Saunier, E. F., Quigley, D., Luu, M. T., De Sapio, A., Hann, B., Yingling, J. M., & Akhurst, R. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2941 · Cited by 82
Self-citationZhao, B. M., & Hoffmann, F. M. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-10-0990 · Cited by 81
Tanaka, H. (2010) · Oncology Reports · doi:10.3892/or_00001028 · Cited by 78
Morris, J. C., Shapiro, G. I., Tan, A. R., Lawrence, D. P., Olencki, T. E., Dezube, B. J., Hsu, F. J., Reiss, M., & Berzofsky, J. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.9028 · Cited by 78
Lindley, L. E., & Briegel, K. J. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.07.138 · Cited by 76
Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
Fiore, F. D., Sesboüé, R., Michel, P., Sabourin, J., & Frébourg, T. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6606008 · Cited by 76
Lücke, C. D., Philpott, A., Metcalfe, J. C., Thompson, A. M., Hughes‐Davies, L., Kemp, P. R., & Hesketh, R. (2001) · PubMed · Cited by 76
Kulkarni, A. B., Thyagarajan, T., & Letterio, J. J. (2002) · Current Molecular Medicine · doi:10.2174/1566524024605699 · Cited by 73
Defective TGF-β signaling sensitizes human cancer cells to rapamycin
Gadir, N., Jackson, D. N., Lee, E., & Foster, D. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210721 · Cited by 66
Qian, S. W., Burmester, J. K., Tsang, M., Weatherbee, J. A., Hinck, A. P., Ohlsen, D. J., Sporn, M. B., & Roberts, A. B. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.48.30656 · Cited by 63
Multipotent adult progenitor cells: their role in wound healing and the treatment of dermal wounds
Herdrich, B. J., Lind, R. C., & Liechty, K. W. (2008) · Cytotherapy · doi:10.1080/14653240802345820 · Cited by 61
Intravital Imaging Illuminates Transforming Growth Factor β Signaling Switches during Metastasis
Giampieri, S., Pinner, S. E., & Sahai, E. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0466 · Cited by 55
Laouar, Y., Gorelik, L., & Flavell, R. A. (2002) · Directions in Science · doi:10.1100/tsw.2002.873 · Cited by 50
Hu, Z., Zhang, Z., Guise, T. A., & Seth, P. K. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.018 · Cited by 49
A fully human antibody neutralising biologically active human TGFβ2 for use in therapy
Thompson, J. E., Vaughan, T. J., Williams, A. J., Wilton, J., Johnson, K. S., Bacon, L., Green, J. A., Field, R. P., Ruddock, S., MARTINS, M. S., et al. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(99)00060-5 · Cited by 44
Seth, P. K., Wang, Z.-G., Pister, A., Zafar, M. B., Kim, S. H., Guise, T. A., & Wakefield, L. M. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.1152 · Cited by 43
Genetic variants of Tgfb1 act as context-dependent modifiers of mouse skin tumor susceptibility
Mao, J., Saunier, E. F., de Koning, J. P., McKinnon, M. L., Higgins, M. N., Nicklas, K., Yang, H., Balmain, A., & Akhurst, R. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602581103 · Cited by 41
Self-citationCalvo, E., Baselga, J. M., Glatt, S., Cleverly, A., Lahn, M., Arteaga, C. L., Rothenberg, M. L., & Carducci, M. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.14554 · Cited by 38
Rodon, J. A., Baselga, J. M., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., Lahn, M., Pillay, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3011 · Cited by 29
The Complexities of TGF-β Action During Mammary and Squamous Cell Carcinogenesis
Connolly, E. C., & Akhurst, R. J. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111798808284 · Cited by 20
Self-citationTumor microenvironments direct the recruitment and expansion of human Th17 cells (100.28)
Peng, G., Su, X., Ye, J., Hsueh, E. C., Zhang, Y., & Hoft, D. F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.184.supp.100.28 · Cited by 18
Two somatic biallelic lesions within and near SMAD4 in a human breast cancer cell line
Jakob, J. A., Nagase, S., Gazdar, A. F., Chien, M., Morozova, I., Russo, J. J., Nandula, S. V., Murty, V. V. V. S., Li, C. M., Tycko, B., et al. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20142 · Cited by 9
Bogdahn, U., Hau, P., Olyushin, V. E., Mahapatra, A. K., Парфенов, В. Е., Venkataramana, N. K., Wassmann, H., Ludwig, S., Heinrichs, H., & Schlingensiepen, K.-H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.2018 · Cited by 7
Cited by
The Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270
Chronic inflammation and cytokines in the tumor microenvironment
Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C., & Hermoso, M. A. (2014) · Journal of Immunology Research · doi:10.1155/2014/149185 · Cited by 1,765
Extracellular matrix and its therapeutic potential for cancer treatment
Huang, J., Zhang, L., Wan, D., Zhou, L., Zheng, S., Lin, S., & Qiao, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00544-0 · Cited by 962
The role of TGF-β/SMAD4 signaling in cancer
Zhao, M., Mishra, L., & Deng, C.-X. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.23230 · Cited by 631
Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets
Di, X., Gao, X., Peng, L., Ai, J., Jin, X., Qi, S., Li, H., Wang, K., & Luo, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01501-9 · Cited by 622
Metadata
- Authors
- Connolly, E. C., Freimuth, J., & Akhurst, R. J.
- Venue
- International Journal of Biological Sciences
- Publisher
- Ivyspring International Publisher
- Published
- 2012
- Volume
- 8
- Issue
- 7
- Pages
- 964-978
- ISSN
- 1449-2288 (ISSN-L)
- OpenAlex
- W2130643308
- Cited by
- 345
- References
- 135
- FWCI
- 10.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.